NCT06625398 (REVEAL-2) is a Phase 3 clinical trial of VRDN-003 in Thyroid Eye Disease, sponsored by Viridian Therapeutics, Inc..

Who is sponsoring NCT06625398?

NCT06625398 is sponsored by Viridian Therapeutics, Inc..

What drugs are being tested in NCT06625398?

Interventions in NCT06625398: VRDN-003, Placebo.

What condition does NCT06625398 study?

NCT06625398 studies Thyroid Eye Disease.

Is NCT06625398 still recruiting?

NCT06625398 is currently active, enrolled. Last updated 30 September 2025.

Last reviewed 2025-09-30 · How we verify

NCT06625398: REVEAL-2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)

Active, enrolled Phase 3 Last updated 30 September 2025

What this trial tests

Phase 3 trial testing VRDN-003 in Thyroid Eye Disease in 195 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

27 August 2024

Primary endpoint
1 April 2026

15 December 2026

Quick facts

Lead sponsor	Viridian Therapeutics, Inc.
Phase	Phase 3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	195
Start date	27 August 2024
Primary completion	1 April 2026
Estimated completion	15 December 2026
Sites	37 locations across United States

Drugs / interventions tested

VRDN-003 — full drug profile →
Placebo

Conditions studied

Thyroid Eye Disease — all drugs for Thyroid Eye Disease →

Sponsor

Viridian Therapeutics, Inc. — full company profile →

Who can join

Adults 18 to 75, any sex, with Thyroid Eye Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with chronic Thyroid Eye Disease (TED).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Antibodies to watch in 2026.
Crescioli S, Kaplon H, Chenoweth A, Hsu YS, et al · · 2026 · PMID 41560619 · DOI 10.1080/19420862.2026.2614669

Verify or expand the search:

Other trials of VRDN-003

Trials testing the same drug.

NCT06625411 — An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) · Phase 3 · active not recruiting

Other recruiting trials for Thyroid Eye Disease

Currently open trials in the same condition.

NCT07423013 — Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease. · NA · recruiting
NCT07113262 — A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease · Phase 3 · recruiting
NCT06557850 — A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease · Phase 1 · active not recruiting
NCT06625411 — An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) · Phase 3 · active not recruiting
NCT06248619 — A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participa · Phase 3 · active not recruiting

Other Viridian Therapeutics, Inc. trials

Trials by the same sponsor.

NCT06625411 — An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) · Phase 3 · active not recruiting
NCT06384547 — A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) · Phase 3 · completed
NCT06179875 — An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301 · Phase 3 · completed
NCT06021054 — An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease ( · Phase 3 · completed
NCT05176639 — A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid E · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06625398 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Viridian Therapeutics, Inc.
Last refreshed: 30 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06625398.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing